288 related articles for article (PubMed ID: 17312304)
1. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Veronesi U; Maisonneuve P; Rotmensz N; Bonanni B; Boyle P; Viale G; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Oliviero P; Lovison F; Gucciardo G; del Turco MR; Muraca MG; Pizzichetta MA; Conforti S; Decensi A;
J Natl Cancer Inst; 2007 May; 99(9):727-37. PubMed ID: 17470740
[TBL] [Abstract][Full Text] [Related]
4. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
Smith SG; Sestak I; Howell A; Forbes J; Cuzick J
J Clin Oncol; 2017 Aug; 35(23):2666-2673. PubMed ID: 28661758
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial.
Hale MJ; Howell A; Dowsett M; Cuzick J; Sestak I
Breast; 2020 Dec; 54():216-221. PubMed ID: 33160147
[TBL] [Abstract][Full Text] [Related]
6. Future possibilities in the prevention of breast cancer: breast cancer prevention trials.
Cuzick J
Breast Cancer Res; 2000; 2(4):258-63. PubMed ID: 11250718
[TBL] [Abstract][Full Text] [Related]
7. Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: A case-control study.
Lin HF; Liao KF; Chang CM; Lin CL; Lai SW; Hsu CY
Medicine (Baltimore); 2018 Dec; 97(51):e12842. PubMed ID: 30572423
[TBL] [Abstract][Full Text] [Related]
8. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
; Davies C; Godwin J; Gray R; Clarke M; Cutter D; Darby S; McGale P; Pan HC; Taylor C; Wang YC; Dowsett M; Ingle J; Peto R
Lancet; 2011 Aug; 378(9793):771-84. PubMed ID: 21802721
[TBL] [Abstract][Full Text] [Related]
9. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Cawthorn S; Mansel RE; Loibl S; Bonanni B; Evans DG; Howell A;
Lancet; 2020 Jan; 395(10218):117-122. PubMed ID: 31839281
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Nordenskjöld A; Fohlin H; Rosell J; Bengtsson NO; Fornander T; Hatschek T; Lindman H; Malmström P; Rydén L; Wallgren A; Stål O; Nordenskjöld B
Breast; 2023 Oct; 71():63-68. PubMed ID: 37517154
[TBL] [Abstract][Full Text] [Related]
11. Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer.
Branigan GL; Soto M; Neumayer L; Rodgers K; Brinton RD
JAMA Netw Open; 2020 Mar; 3(3):e201541. PubMed ID: 32207833
[TBL] [Abstract][Full Text] [Related]
12. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
Garber JE; Halabi S; Tolaney SM; Kaplan E; Archer L; Atkins JN; Edge S; Shapiro CL; Dressler L; Paskett ED; Kimmick G; Orcutt J; Scalzo A; Winer E; Levine E; Shahab N; Berliner N;
J Natl Cancer Inst; 2010 Jul; 102(13):942-9. PubMed ID: 20554945
[TBL] [Abstract][Full Text] [Related]
13. Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials.
Brentnall AR; Cuzick J; Byers H; Segal C; Reuter C; Detre S; Sestak I; Howell A; Powles TJ; Newman WG; Dowsett M
Breast Cancer Res Treat; 2016 Aug; 158(3):591-6. PubMed ID: 27400912
[TBL] [Abstract][Full Text] [Related]
14. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Sestak I; Smith SG; Howell A; Forbes JF; Cuzick J
Ann Oncol; 2018 Feb; 29(2):504-509. PubMed ID: 29126161
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of vascular and neoplastic events associated with tamoxifen.
Braithwaite RS; Chlebowski RT; Lau J; George S; Hess R; Col NF
J Gen Intern Med; 2003 Nov; 18(11):937-47. PubMed ID: 14687281
[TBL] [Abstract][Full Text] [Related]
16. Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.
Llarena NC; Estevez SL; Tucker SL; Jeruss JS
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307641
[TBL] [Abstract][Full Text] [Related]
17. Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
Cuzick J; Brentnall AR; Segal C; Byers H; Reuter C; Detre S; Lopez-Knowles E; Sestak I; Howell A; Powles TJ; Newman WG; Dowsett M
J Clin Oncol; 2017 Mar; 35(7):743-750. PubMed ID: 28029312
[TBL] [Abstract][Full Text] [Related]
18. The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
Smith SG; Sestak I; Morris MA; Harvie M; Howell A; Forbes J; Cuzick J
Breast Cancer Res Treat; 2021 Jul; 188(1):215-223. PubMed ID: 33656637
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic imbalance induced by tamoxifen in estrogen receptor-positive breast cancer patients: An observational study.
Didembourg M; Reda S; Oldenburg J; Rühl H; Douxfils J; Morimont L
Int J Lab Hematol; 2024 Jun; 46(3):546-554. PubMed ID: 38296772
[TBL] [Abstract][Full Text] [Related]
20. Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial.
Land SR; Liu Q; Wickerham DL; Costantino JP; Ganz PA
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):823-32. PubMed ID: 24569437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
